Table I.
Clinical information of patients.
| Clinical information | No. of patients |
|---|---|
| Mean age at time of diagnosis (years) | 55 (33–72) |
| Clinical stage prior to NAC | |
| Stage II | 13 |
| Stage III | 18 |
| Stage IV | 3 |
| Subtype | |
| Luminal A | 9 |
| Luminal B | 9 |
| HER-2 enriched | 8 |
| Triple negative | 8 |
| NAC regimen | |
| EC ×4 | 8 |
| ET ×6 | 18 |
| ETH ×6 | 8 |
| Response to NAC | |
| Progressive disease | 5 |
| Stable disease | 6 |
| Partial response | 18 |
| Complete response | 5 |
NAC, neoadjuvant chemotherapy; EC, epirubicin and cyclophosphamide; EC ×4, EC every 3 weeks for 4 cycles; ET, epirubicin and docetaxel; ETx6: ET every 3 weeks for 6 cycles; ETH, epirubicin, docetaxel and trastuzumab; ETH ×6, ETH every 3 weeks for 6 cycles; HER-2, human epidermal growth factor receptor 2.